News Release
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Puma Biotechnology - Updates, News, Events, Signals & Triggers
Alan H. Auerbach - Los Angeles Business Journal
Puma Biotechnology falls more than 20%
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology Executives Under Investigation for Breast Cancer Drug — Schubert Jonckheer & Kolbe
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
The Prognosis For Puma Biotechnology (NASDAQ:PBYI) | Seeking Alpha
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Stocks to Watch: Dropbox, Nike, Tronc, Qualcomm, Puma Biotechnology, Invitation Homes, Universal Display - WSJ
Why Puma Biotechnology Is Soaring Today | The Motley Fool
Here's Why Puma Biotechnology Fell 17.2% in April | The Motley Fool
Puma Biotechnology Inc
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Should You Buy Puma Biotechnology Inc (PBYI) Stock Tuesday?
Puma Biotechnology - Updates, News, Events, Signals & Triggers
Puma (PBYI): Recent Rally Looks Overdone, Unsupported With Fundamentals | Seeking Alpha
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Goldman Sachs Group Cuts Stake in Puma Biotechnology (PBYI)
